Drugs / F17464
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01689038 | Nov 2012 → Feb 2013 | — | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02151656 | Jun 2014 → Dec 2015 | schizophrenia | Pierre Fabre Laboratories | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F17464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01689038 ↗ |
| Modality | Small molecule | — CHEMBL5316163 ↗ |
| Route | Oral | “Oral administration - During 6 weeks - 4 capsules daily” NCT02151656 ↗ |